INmune Bio (NASDAQ:INMB) and AIM ImmunoTech (NYSE:AIM) Head-To-Head Review

AIM ImmunoTech (NYSE:AIM) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for AIM ImmunoTech and INmune Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIM ImmunoTech	0	0	2	0	3.00
INmune Bio	0	0	3	0	3.00

AIM ImmunoTech presently has a consensus price target of $2.75, indicating a potential upside of 1,002.20%. INmune Bio has a consensus price target of $20.00, indicating a potential upside of 269.69%. Given AIM ImmunoTech’s higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than INmune Bio.

Profitability

This table compares AIM ImmunoTech and INmune Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%
INmune Bio	-26,333.59%	-117.48%	-78.96%

Earnings and Valuation

This table compares AIM ImmunoTech and INmune Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIM ImmunoTech	$190,000.00	83.75	-$28.96 million	($0.47)	-0.53
INmune Bio	$42,000.00	2,855.96	-$30.01 million	($2.18)	-2.48

AIM ImmunoTech has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AIM ImmunoTech has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.

Institutional & Insider Ownership

12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 35.2% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

INmune Bio beats AIM ImmunoTech on 7 of the 13 factors compared between the two stocks.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.